CorMedix Inc. (CRMD) Stock Forecast
CRMD analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.50 / 5 from 6 analysts
- Price target
- $15.33 average of analyst targets
- Upside to target
- +111.2% from the latest close
- Next earnings
- November 11, 2026 EPS estimate $-0.05
- 52-week range
- $6.25 – $12.73
CRMD analyst ratings
6 analystsNumber of analysts at each rating.
CRMD price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
CRMD earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.11 | −$0.17 | −$0.05 | $1.26 | −108.5% | 6 |
| Current fiscal year (2026) | $0.49 | $0.36 | $0.59 | $2.04 | −75.7% | 6 |
| Next fiscal year (2027) | $0.06 | −$0.16 | $0.23 | $0.49 | −88.5% | 6 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
CRMD revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $53.2M | $50.9M | $57.8M | −48.9% | 6 |
| Current fiscal year (2026) | $337.1M | $335.0M | $344.0M | +8.1% | 6 |
| Next fiscal year (2027) | $289.3M | $282.4M | $303.3M | −14.2% | 6 |
CRMD EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
CRMD revenue: reported and forecast
CRMD EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.09 | −$0.09 | −$0.10 | −$0.11 | −$0.11 | +13.5% | 1 up · 2 down |
| Current fiscal year (2026) | $0.50 | $0.50 | $0.49 | $0.49 | $0.49 | −1.8% | 2 up · 3 down |
| Next fiscal year (2027) | $0.09 | $0.09 | $0.06 | $0.06 | $0.06 | −35.6% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
CRMD earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; CRMD beat in 10 of 12.
What analysts expect from CRMD
6 analysts cover CorMedix; their consensus rating is strong buy (4.50 on a 1–5 scale, where 5 is a strong buy). The average price target is $15.33, 111.2% above the latest close of $7.26. Analysts expect earnings of $0.49 per share for 2026, −75.7% from a year earlier. For 2027 the average estimate is $0.06 per share on revenue of $289.3 million. CorMedix beat the EPS estimate in 10 of the last 12 quarters.
Related: CRMD income statement, CRMD key metrics, CRMD chart. See the CRMD stock overview for the latest quote and news.
CRMD forecast FAQ
What is CorMedix's price target?
The average analyst price target for CorMedix is $15.33, 111.2% above the latest close of $7.26.
Is CorMedix a buy, hold or sell?
Of 6 analysts covering CorMedix, 3 rate it a strong buy, 3 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is CorMedix's EPS forecast?
Analysts forecast $0.49 per share for 2026 (range $0.36 to $0.59); for 2027 the estimate is $0.06.
What is CorMedix's revenue forecast?
The average revenue estimate for 2026 is $337.1 million, growth of 8.1%; for 2027 it is $289.3 million.
When does CorMedix report earnings?
CorMedix is expected to report results for the quarter ending September 30, 2026 on November 11, 2026; the EPS estimate is $-0.05.
Does CorMedix usually beat earnings estimates?
CorMedix reported EPS at or above the analyst estimate in 10 of the last 12 quarters.